Board of Directors

Rod Ferguson, PhD – Co-Founder, Panorama Capital

Rod Ferguson is a co-founder of Panorama Capital, a venture capital firm which spun off from JPMorgan Partners (JPMP) in July 2006, where he focuses primarily on life sciences investments. He joined JPMP as a Managing Director in their life sciences venture practice in 2001.

| read more »

Gerald Proehl – Independent Board Member

Gerry Proehl is the former President and CEO of Santarus, Inc. where he led the sale of that company to Salix in early 2014 for $2.6 billion. Prior to Santarus, Mr. Proehl was with Hoechst Marion Roussel for 14 years, where he served in various capacities, including Vice President of Global Marketing.

| read more »

Samuel Saks, MD – Chief Development Office, Director

Sam Saks is a board certified oncologist who was most recently the founding CEO of Jazz Pharmaceuticals until his retirement in 2009. From 2001 until he joined Jazz, Dr. Saks was company group chairman of ALZA Corporation and member of the Johnson & Johnson Pharmaceutical Operating Committee.

| read more »

Sepehr Sarshar, PhD – Auspex Founder and Partner, Sloan Biotech Funds

Sep Sarshar is a partner at Sloan Biotech Funds and is a founder of Auspex. Sep received his PhD From Harvard University under the direction of Professor E. J. Corey. He began his pharmaceutical career at Ontogen Corporation (1994-1997) where he discovered and co-invented ONT-093, a P-glycoprotein pump inhibitor currently in Phase II trials,

| read more »

Phillip Schneider – Independent Board Member

Phil Schneider is the former Chief Financial Officer of IDEC Pharmaceuticals where he served until its sale to Biogen. Since then, Mr. Schneider has served as a Board member for a variety of companies including Arena Pharmaceuticals, Gen-Probe, and CancerVax/Micromet and has frequently served as an Audit Committee Chairperson.

| read more »

Pratik Shah, PhD – President and CEO, Director

Pratik Shah is President and CEO of Auspex. He was previously Executive Chairman of Auspex and has been involved in shaping the company’s strategy since joining the boardin 2007. He has been involved in a number of biotechnology companies and was lead director and founding investor in CNS Therapeutics (acquired by Mallincrodt).

| read more »

Alex Zisson – Partner, Thomas, McNerney & Partners

Alex Zisson is a partner in the venture capital firm Thomas, McNerney & Partners and is also currently a board member of Celator Pharmaceuticals, Inc. (CLPM), Clarus Therapeutics, Inc. and InnoPharma, Inc. Prior to Thomas, McNerney & Partners, he spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan H&Q).

| read more »